Johnson & Johnson has received FDA approval for Icotyde, a once-daily oral pill aimed at treating moderate to severe plaque psoriasis, marking a significant advancement in the competitive psoriasis treatment landscape. This approval positions Icotyde as a potential first-line systemic treatment, bridging the gap between topical medications and injectable therapies, which are often avoided by patients due to needle phobia.
The introduction of Icotyde could disrupt the market dominated by injectable treatments like J&J’s own Tremfya and AbbVie’s Skyrizi, both of which are priced around $100,000 annually. J&J anticipates that Icotyde could generate over $5 billion in peak annual sales as it seeks approval for additional autoimmune conditions. Following the announcement, J&J shares dipped slightly, while AbbVie experienced a more notable decline, reflecting investor concerns about the competitive implications of this new oral treatment.
For market professionals, the approval of Icotyde represents a pivotal moment in the pharmaceutical sector, particularly in autoimmune treatments. To delve deeper into the potential impacts and market dynamics, I recommend exploring the full article for comprehensive insights.
Source: cnbc.com